Lymphoproliferative Disorders Related to Immunodeficiencies

Gross, Thomas G.; Shiramizu, Bruce

doi:10.1007/978-3-540-68753-5_11

Cited by 11 publications

(42 citation statements)

References 197 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The majority of these tumors are of the mature B-cell phenotype and associated with Epstein-Barr virus [3]. Although rarely observed in immunocompetent children and adolescents, B-cell NHL, such as primary CNS lymphoma, pleural effusion lymphoma, MALT lymphoma, and even plasma cell lymphoma, has been reported in the immunodeficient population [3].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pediatric non-Hodgkin’s lymphoma

Gross

Termuhlen²

2007

Curr Oncol Rep

View full text Add to dashboard Cite

Non-Hodgkin's lymphoma (NHL) accounts for 7% of cancer in children and adolescents in the United States, or approximately 1000 cases annually. NHL in the pediatric population differs from that observed in adult patients with respect to staging systems, histologic subtypes of disease, treatment, and outcomes. Although more than 90% of pediatric NHL is of high-grade histology, more than 80% of patients achieve long-term event-free survival with modern therapy. This review focuses on current treatments for pediatric NHL and some of the differences between NHL observed in pediatric and adult patients.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Over 100 cases annually of NHL or lymphoproliferative disorders occur in children or adolescents with a primary or secondary immunodeficiency [3]. The majority of these tumors are of the mature B-cell phenotype and associated with Epstein-Barr virus [3].…”

Section: Introductionmentioning

confidence: 99%

Pediatric non-Hodgkin’s lymphoma

Gross

Termuhlen²

2007

Curr Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Over 100 cases annually of NHL or lymphoproliferative disorders occur in children or adolescents with a primary or secondary immunodefi ciency [ 3 ]. The majority of these tumors are of the mature B-cell phenotype and associated with Epstein-Barr virus [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

“…The majority of these tumors are of the mature B-cell phenotype and associated with Epstein-Barr virus [ 3 ]. Although rarely observed in immunocompetent children and adolescents, B-cell NHL such as primary CNS lymphoma, pleural effusion lymphoma, MALT lymphoma, and even plasma cell lymphoma have been reported in the immunodefi cient population [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

“…Improving immune function is the ultimate goal in the treatment of these patients. This approach consists of effective antiviral therapy for HIV-infected patients, reduction of immunosuppressants in post-transplant patients, or allogeneic bone marrow transplantation (BMT) for patients with severe primary immunodefi ciency [ 3 ]. Usually, the outcome for these patients is inferior to that of immunocompetent children, primarily due to increased toxicity from standard cytotoxic therapies [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pediatric non-Hodgkin lymphoma

Gross

Termuhlen²

2008

Curr Hematol Malig Rep

View full text Add to dashboard Cite

Non-Hodgkin lymphoma (NHL) accounts for 7% of cancer in children and adolescents in the United States, or approximately 1000 cases annually. NHL in the pediatric population differs from that observed in adult patients with respect to staging systems, histologic subtypes of disease, treatment, and outcomes. Although more than 90% of pediatric NHL is of high-grade histology, more than 80% of patients achieve long-term event-free survival with modern therapy. This review focuses on current treatments for pediatric NHL and some of the differences between NHL observed in pediatric and adult patients.

show abstract

Malignancies in the setting of primary immunodeficiency: Implications for hematologists/oncologists

Shapiro¹

2010

American J Hematol

View full text Add to dashboard Cite

Many primary immunodeficiency disorders (PIDD) are associated with elevated risks for different types of cancer. Defective immunosurveillance mechanisms in PIDD and infection with oncogenic viruses (eg, Epstein Barr, herpesvirus 8) seem to have significant contributory roles in many cases. Non‐Hodgkin lymphoma and Hodgkin disease are two of the most common PIDD‐associated malignancies. The impact of PIDD‐associated malignancy has increased in recent years in parallel with improved patient with PIDD survival and longevity, due largely to effective immunoglobulin replacement therapy. Epidemiologic data, clinical patterns, and management considerations of the common PIDD‐associated cancers are reviewed. Am. J. Hematol., 2011. © 2010 Wiley‐Liss, Inc.

show abstract

Lymphoproliferative Disorders Related to Immunodeficiencies

Cited by 11 publications

References 197 publications

Pediatric non-Hodgkin’s lymphoma

Pediatric non-Hodgkin’s lymphoma

Pediatric non-Hodgkin lymphoma

Malignancies in the setting of primary immunodeficiency: Implications for hematologists/oncologists

Contact Info

Product

Resources

About